Incidence and risk factors of neonatal bacterial infections: a community-based cohort from Madagascar (2018-2021).


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
05 Oct 2023
Historique:
received: 23 12 2022
accepted: 25 09 2023
medline: 9 10 2023
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: epublish

Résumé

Few studies on neonatal severe bacterial infection are available in LMICs. Data are needed in these countries to prioritize interventions and decrease neonatal infections which are a primary cause of neonatal mortality. The BIRDY project (Bacterial Infections and Antimicrobial Drug Resistant among Young Children) was initially conducted in Madagascar, Senegal and Cambodia (BIRDY 1, 2012-2018), and continued in Madagascar only (BIRDY 2, 2018-2021). We present here the BIRDY 2 project whose objectives were (1) to estimate the incidence of neonatal severe bacterial infections and compare these findings with those obtained in BIRDY 1, (2) to identify determinants associated with severe bacterial infection and (3) to specify the antibiotic resistance pattern of bacteria in newborns. The BIRDY 2 study was a prospective community-based mother and child cohort, both in urban and semi-rural areas. All pregnant women in the study areas were identified and enrolled. Their newborns were actively and passively followed-up from birth to 3 months. Data on clinical symptoms developed by the children and laboratory results of all clinical samples investigated were collected. A Cox proportional hazards model was performed to identify risk factors associated with possible severe bacterial infection. A total of 53 possible severe bacterial infection and 6 confirmed severe bacterial infection episodes were identified among the 511 neonates followed-up, with more than half occurring in the first 3 days. For the first month period, the incidence of confirmed severe bacterial infection was 11.7 per 1,000 live births indicating a 1.3 -fold decrease compared to BIRDY 1 in Madagascar (p = 0.50) and the incidence of possible severe bacterial infection was 76.3, indicating a 2.6-fold decrease compared to BIRDY 1 in Madagascar (p < 0.001). The 6 severe bacterial infection confirmed by blood culture included 5 Enterobacterales and one Enterococcus faecium. The 5 Enterobacterales were extended-spectrum β-lactamases (ESBL) producers and were resistant to quinolones and gentamicin. Enterococcus faecium was sensitive to vancomycin but resistant to amoxicillin and to gentamicin. These pathogns were classified as multidrug-resistant bacteria and were resistant to antibiotics recommended in WHO guidelines for neonatal sepsis. However, they remained susceptible to carbapenem. Fetid amniotic fluid, need for resuscitation at birth and low birth weight were associated with early onset possible severe bacterial infection. Our results suggest that the incidence of severe bacterial infection is still high in the community of Madagascar, even if it seems lower when compared to BIRDY 1 estimates, and that existing neonatal sepsis treatment guidelines may no longer be appropriate in Madagascar. These results motivate to further strengthen actions for the prevention, early diagnosis and case management during the first 3 days of life.

Sections du résumé

BACKGROUND BACKGROUND
Few studies on neonatal severe bacterial infection are available in LMICs. Data are needed in these countries to prioritize interventions and decrease neonatal infections which are a primary cause of neonatal mortality. The BIRDY project (Bacterial Infections and Antimicrobial Drug Resistant among Young Children) was initially conducted in Madagascar, Senegal and Cambodia (BIRDY 1, 2012-2018), and continued in Madagascar only (BIRDY 2, 2018-2021). We present here the BIRDY 2 project whose objectives were (1) to estimate the incidence of neonatal severe bacterial infections and compare these findings with those obtained in BIRDY 1, (2) to identify determinants associated with severe bacterial infection and (3) to specify the antibiotic resistance pattern of bacteria in newborns.
METHODS METHODS
The BIRDY 2 study was a prospective community-based mother and child cohort, both in urban and semi-rural areas. All pregnant women in the study areas were identified and enrolled. Their newborns were actively and passively followed-up from birth to 3 months. Data on clinical symptoms developed by the children and laboratory results of all clinical samples investigated were collected. A Cox proportional hazards model was performed to identify risk factors associated with possible severe bacterial infection.
FINDINGS RESULTS
A total of 53 possible severe bacterial infection and 6 confirmed severe bacterial infection episodes were identified among the 511 neonates followed-up, with more than half occurring in the first 3 days. For the first month period, the incidence of confirmed severe bacterial infection was 11.7 per 1,000 live births indicating a 1.3 -fold decrease compared to BIRDY 1 in Madagascar (p = 0.50) and the incidence of possible severe bacterial infection was 76.3, indicating a 2.6-fold decrease compared to BIRDY 1 in Madagascar (p < 0.001). The 6 severe bacterial infection confirmed by blood culture included 5 Enterobacterales and one Enterococcus faecium. The 5 Enterobacterales were extended-spectrum β-lactamases (ESBL) producers and were resistant to quinolones and gentamicin. Enterococcus faecium was sensitive to vancomycin but resistant to amoxicillin and to gentamicin. These pathogns were classified as multidrug-resistant bacteria and were resistant to antibiotics recommended in WHO guidelines for neonatal sepsis. However, they remained susceptible to carbapenem. Fetid amniotic fluid, need for resuscitation at birth and low birth weight were associated with early onset possible severe bacterial infection.
CONCLUSION CONCLUSIONS
Our results suggest that the incidence of severe bacterial infection is still high in the community of Madagascar, even if it seems lower when compared to BIRDY 1 estimates, and that existing neonatal sepsis treatment guidelines may no longer be appropriate in Madagascar. These results motivate to further strengthen actions for the prevention, early diagnosis and case management during the first 3 days of life.

Identifiants

pubmed: 37798644
doi: 10.1186/s12879-023-08642-w
pii: 10.1186/s12879-023-08642-w
pmc: PMC10552278
doi:

Substances chimiques

Anti-Bacterial Agents 0
Gentamicins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

658

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

J Infect Dis. 2009 Sep 15;200(6):906-15
pubmed: 19671016
Paediatr Drugs. 2021 Sep;23(5):465-484
pubmed: 34435316
Paediatr Child Health. 2019 May;24(2):e66-e73
pubmed: 30996609
J Perinatol. 2017 Aug;37(8):911-921
pubmed: 28492525
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Trends Mol Med. 2016 Apr;22(4):290-302
pubmed: 26993220
BMC Infect Dis. 2021 Jun 9;21(1):546
pubmed: 34107906
N Engl J Med. 2005 Jan 6;352(1):39-47
pubmed: 15635111
Clin Epidemiol. 2017 Mar 15;9:157-166
pubmed: 28352203
PLoS Med. 2021 Sep 28;18(9):e1003681
pubmed: 34582450
Expert Rev Anti Infect Ther. 2020 May;18(5):443-452
pubmed: 32070161
Lancet Infect Dis. 2014 Aug;14(8):731-741
pubmed: 24974250
Arch Dis Child. 2013 Feb;98(2):146-54
pubmed: 23142784
Pediatr Infect Dis J. 1991 Oct;10(10):752-7
pubmed: 1945577
Nat Microbiol. 2021 Apr;6(4):512-523
pubmed: 33782558
Lancet Glob Health. 2020 Jul;8(7):e909-e919
pubmed: 32562647
J Pediatr. 2018 Oct;201:106-114.e4
pubmed: 30054165
Obstet Gynecol. 2021 Jun 1;137(6):1007-1022
pubmed: 33957655
J Clin Microbiol. 2000 Jun;38(6):2181-5
pubmed: 10834973
BMJ. 2020 Oct 1;371:m3672
pubmed: 33004379
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Pediatr Infect Dis J. 2011 Nov;30(11):937-41
pubmed: 21654548
Lancet. 2018 Jul 14;392(10142):145-159
pubmed: 30025808
Indian J Pediatr. 2011 Apr;78(4):409-12
pubmed: 20953913
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651

Auteurs

Ines Devred (I)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, F-75015, France.

Lison Rambliere (L)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, F-75015, France.

Perlinot Herindrainy (P)

Epidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Lovarivelo Andriamarohasina (L)

Epidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Aina Harimanana (A)

Epidemiology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Frederique Randrianirina (F)

Centre de biologie clinique, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Elisoa Hariniaina Ratsima (EH)

Centre de biologie clinique, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Delphine Hivernaud (D)

Hôpital Necker-Enfants malades, Department of Neonatal medicine, AP-HP, Université Paris Cité, Paris, France.

Elsa Kermorvant-Duchemin (E)

Hôpital Necker-Enfants malades, Department of Neonatal medicine, AP-HP, Université Paris Cité, Paris, France.

Zafitsara Zo Andrianirina (ZZ)

Peadiatric Ward, Centre Hospitalier de Soavinandriana, Antananarivo, Madagascar.

Armya Youssouf Abdou (AY)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, F-75015, France.

Elisabeth Delarocque-Astagneau (E)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Medical Information, AP-HP. Paris Saclay, Public Health, Clinical research, Le Kremlin-Bicêtre, F-94276, France.

Didier Guillemot (D)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France.
Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, F-75015, France.
Medical Information, AP-HP. Paris Saclay, Public Health, Clinical research, Le Kremlin-Bicêtre, F-94276, France.

Tania Crucitti (T)

Experimental Bacteriology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Jean-Marc Collard (JM)

Experimental Bacteriology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Bich-Tram Huynh (BT)

CESP, Anti-infective evasion and pharmacoepidemiology team, Université Paris-Saclay, UVSQ, Inserm, Montigny-Le-Bretonneux, F- 78180, France. bich-tram.huynh@pasteur.fr.
Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, F-75015, France. bich-tram.huynh@pasteur.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH